Clinical Radiology
Volume 64, Issue 11 , Pages 1045-1047 , November 2009

Will MRI screening deliver the expected survival advantage in BRCA 1 carriers?

  • L.J. Hamilton

      Affiliations

    • Corresponding Author InformationGuarantor and correspondent: L. J. Hamilton, Nottingham Breast Institute, Nottingham City Hospital, Hucknall Road, Nottingham, NG5 1PB, UK. Tel.: +44 115 9691169x55034.
    • ,
  • A.J. Evans
    • ,
  • E.J. Cornford

References 

  1. Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med. 2004;351:427–437
  2. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet. 2005;365:1769–1778
  3. Pisano ED, Gatsonis C, Hendrick E, et al., Digital Mammographic Imaging screening Trial (DMIST) Investigators group  Diagnostic performance of digital versus film mammography for breast cancer screening. N Engl J Med. 2005;353:1773–1783
  4. Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA. 2004;292:1317–1325
  5. Hamilton LJ, Evans AJ, Wilson AR, et al. Breast imaging findings in women with BRCA-1 and BRCA-2 associated breast carcinoma. Clin Radiol. 2004;59:895–902
  6. Tilanus-Linthorst M, Verhoog L, Obdeijn IM, et al. A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a false negative mammography. Int J Cancer. 2002;102:91–95
  7. Familial breast cancer — the classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care. NICE Clinical guideline 41 London: NICE; 2006;
  8. Tabar L, Chen H-H, Duffy SW, et al. A novel method for prediction of long-term outcome of women with T1a, T1b and 10-14mm invasive cancers: a prospective study. Lancet. 2000;335:429–433
  9. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol. 2008;20:2568–2581
  10. Van De Rijn M, Perou CM, Tibshirani R, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with a poor clinical outcome. Am J Pathol. 2002;161:1991–1996
  11. Luck AA, Evans AJ, Green AR, et al. The influence of basal phenotype on the metastatic pattern of breast cancer. Clin Oncol. 2008;20:40–45
  12. Foulkes WD, Brunet JS, Stefansson IM, et al. The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res. 2004;64:830–835
  13. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429–4434
  14. Foulkes WD, Grainge MJ, Rakha EA, et al. Tumor size is an unreliable predictor of prognosis in basal-like breast cancers and does not correlate closely with lymph node status. Breast Cancer Res Treat. 2008 Jul 4;Epub ahead of print
  15. Evans AJ, Rakha EA, Pinder SE, et al. Basal phenotype: a powerful prognostic factor in small screen-detected invasive breast cancer with long term follow-up. J Med Screen. 2007;14:210–214
  16. Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2003;95:1482–1485
  17. Turner NC, Reis-Filho JS, Russell AM, et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene. 2007;26:2126–2132
  18. Rennert G, Bisland-Naggan S, Barnett-Griness O, et al. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med. 2007;12(357):115–123

PII: S0009-9260(09)00209-8

doi: 10.1016/j.crad.2009.05.008

Clinical Radiology
Volume 64, Issue 11 , Pages 1045-1047 , November 2009

Article Tools